Dr. Bellail grew up along the coast of Normandy in France. She received her BA in Cell Biology, MSc in Biochemistry and PhD in neuroscience from the University of Caen in France. Under the support of the French Association for Cancer Research scholarship,, she came to the US in 2002 and started her postdoctoral training at the Winship Cancer Institute of Emory University, Atlanta.
Dr. Bellail became Assistant Professor of Neurology and Neurological Surgery of the Montreal Neurological Institute at McGill University in Canada in 2013. She moved back to the US and worked at the Henry Ford Health System Research Institute, Michigan. In January 2018, Dr. Bellail was recruited to the Indiana University School of Medicine as an Assistant Professor of Pathology and Laboratory Medicine.
Dr. Bellail started her research on ubiquitin posttranslational modification pathways in regulation of cancer cell programed death in human cancer. Her laboratory then demonstrated that the posttranslational pathway of small ubiquitin modifier-1 (SUMO1) drives the cell cycle and cancer progression. In a cancer cell-based drug screening of NCI small molecule laboratory, her team identified the SUMO1 inhibition compound (SMIC1). Her current research aims to develop SMIC1 as a new anticancer drug for clinical cancer therapy and unveil SMIC1 targeted molecular pathways in human cancer.